| Basics |
Voyager Therapeutics, Inc.
Voyager Therapeutics Inc in collaboration with Genzyme, conducts research and development work to develop therapies for the treatment of central nervous system disorders. It targets diseases such as Parkinson's, Alzheimer's Huntington's.
|
| IPO Date: |
November 11, 2015 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$237.97M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.33 | 3.10%
|
| Avg Daily Range (30 D): |
$0.12 | 2.83%
|
| Avg Daily Range (90 D): |
$0.14 | 3.38%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.46M |
| Avg Daily Volume (30 D): |
.44M |
| Avg Daily Volume (90 D): |
.62M |
| Trade Size |
| Avg Trade Size (Sh.): |
125 |
| Avg Trade Size (Sh.) (30 D): |
82 |
| Avg Trade Size (Sh.) (90 D): |
104 |
| Institutional Trades |
| Total Inst.Trades: |
570 |
| Avg Inst. Trade: |
$1.4M |
| Avg Inst. Trade (30 D): |
$.83M |
| Avg Inst. Trade (90 D): |
$.94M |
| Avg Inst. Trade Volume: |
.12M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.69M |
| Avg Closing Trade (30 D): |
$.86M |
| Avg Closing Trade (90 D): |
$.88M |
| Avg Closing Volume: |
139.75K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
$-2.17
|
$-.47
|
$-.57
|
|
Diluted EPS
|
$-2.17
|
$-.47
|
$-.57
|
|
Revenue
|
$ 31.32M
|
$ 13.37M
|
$ 5.2M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -126.78M
|
$ -27.89M
|
$ -33.38M
|
|
Operating Income / Loss
|
$ -140.21M
|
$ -30.59M
|
$ -36.63M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ -64.66M
|
$ 3.93M
|
$ -30.82M
|
|
PE Ratio
|
|
|
|
|
|
|
